Drug-Linker Conjugates for ADC

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

Drug-Linker Conjugates for ADC

The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.

The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.

Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.

Drug-Linker Conjugates for ADC related products

Cat No.	Product Name	CAS No.	Product Description
V76159	(1R)-Deruxtecan	2270986-87-1	(1R)-Deruxtecan is a drug linker conjugate of ADC.
V53011	(Aminooxy)acetamide-Val-Cit-PAB-MMAE	2446645-88-9	(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthesis/preparation of drug-linker conjugates for the preparation of ADCs.
V77364	(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1)		(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1.
V54777	2',3'-cGAMP-C2-PPA	2586047-11-0	2',3'-cGAMP-C2-PPA is a cyclic dinucleotide stimulating protein of interferon genes (STING) agonist.
V111070	2-MSP-5-HA-VA-PAB-Exatecan	2878440-72-1	2-MSP-5-HA-Val-Cit-PAB-Exatecan (A-24) is a drug-linker conjugate for antibody-drug conjugates (ADCs).
V114221	2-MSP-5-HA-VC-PAB-MMAE	2878440-80-1	2-MSP-5-HA-VC-PAB-MMAE (compound B-1) is an antibody-drug conjugate (ADC)-drug linker conjugate.
V51701	680C-91	163239-22-3	TDO inhibitor
V77295	Ac-Lys-Val-Cit-PABC-MMAE formic		Ac-Lys-Val-Cit-PABC-MMAE (formic) is part of the antibody conjugate active molecule ADC.
V35242	AcLysValCit-PABC-DMAE-SW-163D	2411007-69-5	AcLysValCit-PABC-DMAE-SW-163D is part of the active antibody coupling molecule (drug-linker conjugates for ADC), which is made up of natural dual intercalator SW-163D and linker AcLysValCitPABC-DMAE coupling.
V110531	ADC 38 drug linker		ADC 38 is a drug linker conjugate for antibody-drug conjugates (ADCs) that contains a CD4 mimic and a linker.
V115115	ADC-VI	3031725-06-8	ADC-VI (compound 6) is a conjugate of a toxic molecule and a linker, in which CPD6 carries the cytotoxic drug drutecan.
V88381	Amino-PEG4-GGFG-Dxd	2879227-88-8	Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate composed of Dxd and linker, which can be used for the synthesis of ADC.
V88382	Aminocaproyl-Val-Cit-PABC-MMAE	1374407-35-8	Aminocaproyl-Val-Cit-PABC-MMAE is a drug-linker conjugate used in the synthesis of ADC.
V93149	Aniline-PEG3-C1-Boc	2115897-27-1	Aniline-PEG3-C1-Boc (Compound D-1) is an intermediate for polymer-linked cytotoxic drugs.
V118421	APL-1082	2921735-93-3	APL-1082 (Mc-exo-EVC-Exatecan) is a drug-linker conjugate that can be used in ADC synthesis. Its structure contains Exatecan (ADC payload) and a linker.
V104596	APL-1092	2921735-91-1	APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker complex that can be used for ADC synthesis.
V88401	APN-PEG5-VC-PAB-MMAE		APN-PEG5-VC-PAB-MMAE is the drug-linker conjugate portion of INA03, a transferrin-competitive antibody-drug conjugate targeting CD71.
V3218	ATAC21	2101204-23-1	ATAC21 is a linker immunostimulatory compound formed by conjugating a non-cleavable (non-degradable) maleimide-PEG4 linker containing a succinimide group to an immunostimulatory compound.
V77219	Azide-PEG4-VC-PAB-Doxorubicin		Azide-PEG4-VC-PAB-Doxorubicin is made up of linker Azide-PEG4-VC-PAB and toxic molecule Doxorubicin, and may be utilized to prepare antibody-drug-conjugates/ADCss.
V54765	Azido-PEG4-Val-Cit-PAB-MMAE	1869126-64-6	Azido-PEG4-Val-Cit-PAB-MMAE is part of the antibody conjugate active molecule (drug-linker conjugate for ADC).